BioAtla, Inc. (BCAB) Price Target Analysis
Updated Apr 17, 2026
Analyst Rating: Buy
Based on 9 analysts6739.9% Below Target
BCAB trades 6739.9% below Wall Street's consensus target of $250.00.
Current Price$3.65
Average Target$250.00
Low$250.00
Median$250.00
High$250.00
Analyst Target Range
Forward P/E—
PEG Ratio—
Implied Growth-36.5%
(Declining)
Analyst Spread0.0%
(High Agreement)
Price Forecast (1 Year)
Last 12 months price action with 12-month analyst target path
Consensus Scenario Assumptions
The base valuation assumes BCAB achieves its forward estimates and maintains a stable P/E multiple of historical averagesx. This scenario reflects the blended consensus of 9 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
BCAB Price Target Analysis
Updated June 22, 2026As of June 22, 2026, BioAtla, Inc. (BCAB) has a Wall Street consensus price target of $250.00, based on estimates from 9 covering analysts. With the stock currently trading at $3.65, this represents a potential upside of +6739.9%. The company has a market capitalization of $5M.
Analyst price targets range from a low of $250.00 to a high of $250.00, representing a 0% spread in expectations. The median target of $250.00 aligns closely with the consensus average. The tight target dispersion indicates high conviction among analysts.
The current analyst consensus rating is Buy, with 6 analysts rating the stock as a Buy or Strong Buy,3 rating it Hold, and 0 rating it Sell or Strong Sell. The positive sentiment balance indicates moderate optimism about the stock prospects.
From a valuation perspective, BCAB trades at a trailing P/E of -0.1x. Analysts expect EPS to grow -36.5% over the next year.
Investment Context: Price targets represent analyst expectations for the next 12 months and should be considered alongside your own research. Targets are based on analysts' assumptions about earnings growth, margins, and market conditions which may change. For sector-specific context, view other Healthcare stocks.
Analyst Sentiment Comparison
Industry Peer AnalysisAvg Peer Upside
+74.4%
Industry Consensus
Avg Forward P/E
8.5x
(Value)
Peers with Coverage
10 / 10
Active Analyst Tracking
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 IMVTImmunovant, Inc. | $7.3B | $35.34 | $45.00 | +27.3% | Buy | — | 23 |
 RCUSArcus Biosciences, Inc. | $2.4B | $24.31 | $31.00 | +27.5% | Buy | — | 18 |
 AGENAgenus Inc. | $125M | $3.00 | $7.33 | +144.3% | Buy | 3.8x | 11 |
 MGNXMacroGenics, Inc. | $263M | $4.13 | $6.00 | +45.3% | Buy | — | 22 |
 FATEFate Therapeutics, Inc. | $244M | $2.09 | $5.50 | +163.2% | Buy | — | 31 |
 MIRMMirum Pharmaceuticals, Inc. | $5.4B | $107.13 | $144.91 | +35.3% | Buy | — | 18 |
 ARVNArvinas, Inc. | $495M | $7.67 | $14.75 | +92.3% | Buy | — | 26 |
 NKTRNektar Therapeutics | $1.2B | $60.98 | $149.60 | +145.3% | Buy | — | 33 |
 AGIOAgios Pharmaceuticals, Inc. | $2.0B | $34.16 | $43.33 | +26.8% | Buy | — | 29 |
 REGNRegeneron Pharmaceuticals, Inc. | $63.4B | $609.94 | $836.00 | +37.1% | Buy | 13.1x | 48 |
BCAB — Frequently Asked Questions
Quick answers to the most common questions about buying BCAB stock.
What is the BCAB stock price target for 2026?
The consensus Wall Street price target for BCAB is $250, representing 6739.9% upside from the current price of $3.655. With 9 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
Is BCAB a buy, sell, or hold?
BCAB has a consensus rating of "Buy" based on 9 Wall Street analysts. The rating breakdown is predominantly bullish, with 6 Buy/Strong Buy ratings. The consensus 12-month price target of $250 implies 6739.9% upside from current levels.
Is BCAB stock overvalued or undervalued?
BCAB's current price is $3.655 with a consensus target of $250 (6739.9% implied move). Analyst estimates suggest the stock is undervalued at current levels.
How high can BCAB stock go?
The most bullish Wall Street analyst has a price target of $250 for BCAB, while the most conservative target is $250. The consensus of $250 represents the median expectation. These targets typically reflect 12-month expectations.
How many analysts cover BCAB stock?
BCAB is moderately covered, with 9 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 6 have Buy ratings, 3 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
What is the BCAB stock forecast?
The 12-month BCAB stock forecast based on 9 Wall Street analysts shows a consensus price target of $250, with estimates ranging from $250 (bear case) to $250 (bull case). The median consensus rating is "Buy".
Should I buy BCAB stock?
Wall Street analysts are very optimistic on BCAB, with a "Buy" consensus rating and $250 price target (6739.9% upside). 6 of 9 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
Why do BCAB price targets vary so much?
BCAB analyst price targets range from $250 to $250, a 0% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $250 consensus represents the middle ground.
Consensus-Based Analysis Tools
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Check Valuation
Historical Returns
10-year return with dividends reinvested.
Calculate
DCA Calculator
See how regular investing compounds over time.
Run Numbers
Peer Comparison
Compare growth, multiples, and margins vs sector.
Compare